Septerna, Inc. (SEPN) Stock Analysis and Metrics

Sector: Healthcare Industry: Biotechnology CIK: 0001984086

P/B 2.97

P/E -19.64

P/S 52.40

Market Cap 1.16 Bn

ROIC (Qtr) -18.89

Div Yield % 0.00

Rev 1y % (Qtr) 12,113.07

Total Debt (Qtr) 24.11 Mn

Debt/Equity (Qtr) 0.06

About

Strong operating cash flow of 104.22M provides robust 4.32x coverage of total debt 24.11M, indicating excellent debt servicing capability and financial flexibility.
Healthy cash reserves of 320.89M provide 151.58x coverage of short-term debt 2.12M, demonstrating strong liquidity position and minimal refinancing risk.
Strong tangible asset base of 606.65M provides 25.16x coverage of total debt 24.11M, indicating robust asset backing and low credit risk.
Operating cash flow of 104.22M provides strong 14.71x coverage of stock compensation 7.08M, indicating sustainable incentive practices.
Robust free cash flow of 103.15M exceeds capital expenditure of 1.06M by 96.86x, indicating strong organic growth funding capability.

Operating cash flow of 104.22M barely covers its investment activities of (177.29M), with a coverage ratio of -0.59, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
Investment activities of (177.29M) provide weak support for R&D spending of 85.04M, which is -2.08x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
Operating cash flow of 104.22M provides insufficient coverage of deferred revenue obligations of 182.25M, which is 0.57x, raising concerns about future service delivery capabilities.
Operating cash flow of 104.22M provides minimal -651.37x coverage of tax expenses of (160000), suggesting potential tax planning inefficiencies or unsustainable tax positions.
Operating earnings of (58.97M) show weak coverage of depreciation charges of 3.65M, with a -16.16 ratio indicating high capital intensity and potential reinvestment needs.

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	SMMT	Summit Therapeutics Inc.	1,349.40 Bn	-1,464.17	0.00	0.01 Bn
2	ONC	BeOne Medicines Ltd.	437.43 Bn	6,381.20	87.97	1.90 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	116.09 Bn	31.59	9.90	1.83 Bn
4	REGN	Regeneron Pharmaceuticals, Inc.	78.10 Bn	17.06	5.48	2.71 Bn
5	ALNY	Alnylam Pharmaceuticals, Inc.	55.87 Bn	1,282.42	17.40	3.21 Bn
6	ARGX	Argenx Se	52.85 Bn	35.08	27,559.65	-
7	BNTC	Benitec Biopharma Inc.	41.75 Bn	-998.33	0.00	0.00 Bn
8	INSM	INSMED Inc	37.80 Bn	-31.93	84.56	0.74 Bn

Metric	Value	Industry
EV to Assets	1.63	12.31
EV to Cash from Ops.	9.49	23.25
EV to Debt	41.04	738.44
EV to EBIT	-16.78	-9.16
EV to EBITDA	-13.49	6.95
EV to Free Cash Flow [EV/FCF]	9.59	21.90
EV to Market Cap	0.86	65.67
EV to Revenue	44.88	227.32
Price to Book Value [P/B]	2.97	22.34
Price to Earnings [P/E]	-19.64	-11.77

Metric	Value	Industry	Percentile
Dividend Coverage Ratio	0.00	-11.94
Dividend Payout Ratio %	0.00	0.16
Dividend per Basic Share	0.00	0.01
FCF Dividend Payout Ratio %	0.00	-0.14
Interest Coverage	0.00	841.00

Metric	Value	Industry
Capex Growth (1y) %	60.99	-27.13
Cash and Equivalents Growth (1y) %	259.96	734.65
Dividend Growth (1y) %	0.00	0.01
EBIAT Growth (1y) %	-196.28	-46.93
EBITDA Growth (1y) %	-279.04	-1.68
EBIT Growth (1y) %	-202.47	-56.45
EBT Growth (1y) %	-202.47	-12.70
EPS Growth (1y) %	374.80	-28.31
FCF Growth (1y) %	277.73	-31.90
Gross Profit Growth (1y) %	2,147.20	226.84

Metric	Value	Industry
Asset Utilization Ratio	0.04	0.14
Cash Payout Ratio	0.00	0.00
Cash Ratio	4.26	3.85
Current Ratio	6.53	7.27
Debt to Equity Ratio	0.06	0.40
Interest Cover Ratio	0.00	841.00
Times Interest Earned	0.00	841.00

Metric	Value	Industry
EBITDA Margin %	-250.90	-18,234.31
EBIT Margin %	-267.49	-18,580.80
EBT Margin %	-267.49	-19,488.74
Gross Margin %	100.00	-7.59
Net Profit Margin %	-266.80	-19,439.22